Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158
Diabetes Care
.
2015 Mar;38(3):538.
doi: 10.2337/dc15-er03.
Authors
Michael Nauck
,
Ruth S Weinstock
,
Guillermo E Umpierrez
,
Bruno Guerci
,
Zachary Skrivanek
,
Zvonko Milicevic
PMID:
25715416
PMCID:
PMC5321253
DOI:
10.2337/dc15-er03
No abstract available
Publication types
Published Erratum